Search

Your search keyword '"Formisano, Barbara"' showing total 24 results
Start Over Author "Formisano, Barbara"
24 results on '"Formisano, Barbara"'

1. Adding fasting‐mimicking diet to first‐line carboplatin‐based chemotherapy is associated with better overall survival in advanced triple‐negative breast cancer patients: A subanalysis of the NCT03340935 trial

Author

Ligorio, Francesca, primary, Lobefaro, Riccardo, additional, Fucà, Giovanni, additional, Provenzano, Leonardo, additional, Zanenga, Lucrezia, additional, Nasca, Vincenzo, additional, Sposetti, Caterina, additional, Salvadori, Giulia, additional, Ficchì, Angela, additional, Franza, Andrea, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Formisano, Barbara, additional, Depretto, Catherine, additional, Scaperrotta, Gianfranco, additional, Belfiore, Antonino, additional, Vingiani, Andrea, additional, Ferraris, Cristina, additional, Pruneri, Giancarlo, additional, de Braud, Filippo, additional, and Vernieri, Claudio, additional

Published
2023
Full Text
View/download PDF

2. Adding fasting‐mimicking diet to first‐line carboplatin‐based chemotherapy is associated with better overall survival in advanced triple‐negative breast cancer patients: A subanalysis of the NCT03340935 trial.

Author

Ligorio, Francesca, Lobefaro, Riccardo, Fucà, Giovanni, Provenzano, Leonardo, Zanenga, Lucrezia, Nasca, Vincenzo, Sposetti, Caterina, Salvadori, Giulia, Ficchì, Angela, Franza, Andrea, Martinetti, Antonia, Sottotetti, Elisa, Formisano, Barbara, Depretto, Catherine, Scaperrotta, Gianfranco, Belfiore, Antonino, Vingiani, Andrea, Ferraris, Cristina, Pruneri, Giancarlo, and de Braud, Filippo

Subjects
TRIPLE-negative breast cancer, CANCER patients, OVERALL survival, LOW-calorie diet, CANCER chemotherapy
Abstract

Severe calorie restriction, in the form of cyclic fasting or fasting‐mimicking diets (FMDs), boosts the antitumor activity of cytotoxic chemotherapy in mouse models of triple‐negative breast cancer (TNBC). This effect is mostly mediated by fasting/FMD‐induced reduction of plasma glucose concentration and by a boost in antitumor immunity. However, clinical evidence that cyclic FMD may impact on the outcomes of advanced TNBC (aTNBC) patients is lacking. We compared the overall survival (OS) of 14 aTNBC patients receiving first‐line carboplatin‐gemcitabine plus cyclic FMD in the context of the NCT03340935 trial with the OS of 76 consecutive aTNBC patients treated with carboplatin‐based chemotherapy alone at Fondazione IRCCS Istituto Nazionale dei Tumori. Multivariable Cox regression models were used to adjust the prognostic impact of FMD for other prognostic variables. Patients undergoing cyclic FMD in combination with carboplatin‐gemcitabine had better OS when compared to patients receiving chemotherapy alone (median OS 30.3 months, 95% CI 18‐NR, vs 17.2 months, 95% CI 15.3‐25.1, log‐rank P value.041). Multivariable analysis confirmed an association between FMD use and better OS (HR: 0.40; 95% CI: 0.19‐0.86; P =.019) also after propensity score‐based matching according to patient ECOG PS and the presence of de novo metastatic disease (HR: 0.41; 95% CI: 0.21‐0.83; P =.013). Cyclic FMD in combination with first‐line chemotherapy may improve clinical outcomes in aTNBC patients. Our study paves the way for conducting phase II trials to investigate if cyclic FMD can increase the antitumor activity/efficacy of chemotherapy or chemoimmunotherapy in patients with early‐stage TNBC or aTNBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

3. The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

Author

Provenzano, Leonardo, primary, Lobefaro, Riccardo, additional, Ligorio, Francesca, additional, Zattarin, Emma, additional, Zambelli, Luca, additional, Sposetti, Caterina, additional, Presti, Daniele, additional, Montelatici, Giulia, additional, Ficchì, Angela, additional, Martinetti, Antonia, additional, Arata, Alessio, additional, Del Vecchio, Marta, additional, Lauria Pantano, Claudia, additional, Formisano, Barbara, additional, Bianchi, Giulia Valeria, additional, Capri, Giuseppe, additional, de Braud, Filippo, additional, Vernieri, Claudio, additional, and Fucà, Giovanni, additional

Published
2023
Full Text
View/download PDF

4. sj-docx-10-tam-10.1177_17588359231165978 – Supplemental material for The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis

Author

Provenzano, Leonardo, Lobefaro, Riccardo, Ligorio, Francesca, Zattarin, Emma, Zambelli, Luca, Sposetti, Caterina, Presti, Daniele, Montelatici, Giulia, Ficchì, Angela, Martinetti, Antonia, Arata, Alessio, Del Vecchio, Marta, Lauria Pantano, Claudia, Formisano, Barbara, Bianchi, Giulia Valeria, Capri, Giuseppe, de Braud, Filippo, Vernieri, Claudio, and Fucà, Giovanni

Subjects
110203 Respiratory Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental material, sj-docx-10-tam-10.1177_17588359231165978 for The pan-immune-inflammation value is associated with clinical outcomes in patients with advanced TNBC treated with first-line, platinum-based chemotherapy: an institutional retrospective analysis by Leonardo Provenzano, Riccardo Lobefaro, Francesca Ligorio, Emma Zattarin, Luca Zambelli, Caterina Sposetti, Daniele Presti, Giulia Montelatici, Angela Ficchì, Antonia Martinetti, Alessio Arata, Marta Del Vecchio, Claudia Lauria Pantano, Barbara Formisano, Giulia Valeria Bianchi, Giuseppe Capri, Filippo de Braud, Claudio Vernieri and Giovanni Fucà in Therapeutic Advances in Medical Oncology

Published
2023
Full Text
View/download PDF

9. A randomized phase II trial of maintenance oral metronomic vinorelbine versus close observation in advanced non-small cell lung cancer (NSCLC) following platinum-based chemotherapy: MA.NI.LA. trial.

Author

Platania, Marco, primary, Nichetti, Federico, additional, Porcu, Luca, additional, Pasini, Felice, additional, Boeri, Mattia, additional, Modena, Yasmina, additional, Del Conte, Alessandro, additional, Martinetti, Antonia, additional, Sottotetti, Elisa, additional, Pozzessere, Daniele, additional, Vattemi, Emanuela, additional, Verderame, Francesco, additional, Cavanna, Luigi, additional, Fraccon, Anna Paola, additional, Formisano, Barbara, additional, Gallucci, Rosaria, additional, Lo Russo, Giuseppe, additional, Torri, Valter, additional, and De Braud, Filippo G., additional

Published
2018
Full Text
View/download PDF

10. Metformin with everolimus and octreotide in pancreatic neuroendocrine tumor patients with diabetes

Author

Pusceddu, Sara, primary, Buzzoni, Roberto, additional, Vernieri, Claudio, additional, Concas, Laura, additional, Marceglia, Sara, additional, Giacomelli, Luca, additional, Milione, Massimo, additional, Leuzzi, Livia, additional, Femia, Daniela, additional, Formisano, Barbara, additional, Mazzaferro, Vincenzo, additional, and de Braud, Filippo, additional

Published
2016
Full Text
View/download PDF

12. Bax Expression Is Predictive of Favorable Clinical Outcome in Chemonaive Advanced Gastric Cancer Patients Treated with Capecitabine, Oxaliplatin, and Irinotecan Regimen1

Author

Pietrantonio, Filippo, Biondani, Pamela, de Braud, Filippo, Pellegrinelli, Alessandro, Bianchini, Giampaolo, Perrone, Federica, Formisano, Barbara, and Di Bartolomeo, Maria

Subjects
Research Article
Abstract

OBJECTIVE: Bax protein is a key mediator of apoptosis, and it might be related to chemosensitivity. The purpose of this study was to evaluate the prognostic role of Bax in patients with advanced gastric cancer treated with triplet chemotherapy COI regimen (capecitabine, oxaliplatin, and irinotecan). METHODS: Pretreatment tissue blocks were available for 23 consecutive patients, selected for good performance status (ECOG ≤ 1) and consenting for treatment with first-line COI at a single institution. Bax levels were classified as positive or negative by immunohistochemistry (bax N20; Santa Cruz Biotechnology) and related to outcome in terms of response rate, progression-free survival, and overall survival. RESULTS: Bax-negative and -positive samples were 26% and 74%, respectively. Bax expression was associated with significantly higher response rate (87% vs 33%), progression-free survival (8.7 vs 4.9 months, P = .016), and overall survival (23.8 vs 12.7 months, P = .025). In multivariate analysis including Bax and performance status, low Bax independently predicted worse outcome, along with suboptimal performance status. CONCLUSIONS: In advanced gastric cancer, Bax expression was related to clinical benefit with COI regimen. Whether Bax is a prognostic or mixed prognostic/predictive factor warrants prospective confirmation. It is to be defined if Bax predicts sensitivity to platinum analogs or to whatever chemotherapy regimen.

Published
2012

13. Abstract 1189: The impact of metformin on progression-free survival in patients with advanced pancreatic well differentiated neuroendocrine tumor receiving everolimus plus somatostatin analogue treatment

Author

Pusceddu, Sara, primary, Buzzoni, Roberto, additional, Concas, Laura, additional, Bregant, Cristina, additional, Leuzzi, Livia, additional, Milione, Massimo, additional, Seregni, Ettore, additional, Formisano, Barbara, additional, Consonni, Paola, additional, and De Braud, Filippo, additional

Published
2015
Full Text
View/download PDF

14. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review

Author

Pusceddu, Sara, primary, De Braud, Filippo, additional, Festinese, Fabrizio, additional, Bregant, Cristina, additional, Lorenzoni, Alice, additional, Maccauro, Marco, additional, Milione, Massimo, additional, Concas, Laura, additional, Formisano, Barbara, additional, Leuzzi, Livia, additional, Mazzaferro, Vincenzo, additional, and Buzzoni, Roberto, additional

Published
2015
Full Text
View/download PDF

15. Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

Author

Bajetta, Emilio, primary, Pietrantonio, Filippo, additional, Buzzoni, Roberto, additional, Ferrario, Erminia, additional, Valvo, Francesca, additional, Mariani, Luigi, additional, Dotti, Katia F., additional, Biondani, Pamela, additional, Formisano, Barbara, additional, Gevorgyan, Arpine, additional, Grassi, Paolo, additional, and Di Bartolomeo, Maria, additional

Published
2014
Full Text
View/download PDF

16. The impact of metformin on progression-free survival of patients with advanced pancreatic well-differentiated neuroendocrine tumor receiving everolimus plus somatostatin analog treatment.

Author

Pusceddu, Sara, primary, Buzzoni, Roberto, additional, Giacomelli, Luca, additional, Mazzaferro, Vincenzo, additional, Concas, Laura, additional, Milione, Massimo, additional, Formisano, Barbara, additional, D'Autilia, Elisa, additional, Festinese, Fabrizio, additional, and De Braud, Filippo G., additional

Published
2014
Full Text
View/download PDF

17. Loss of succinate dehydrogenase (SDHB) in midgut carcinoids as a prognostic factor: A new marker of personalized cancer medicine in neuroendocrine tumors?

Author

De Braud, Filippo G., primary, Pusceddu, Sara, additional, Milione, Massimo, additional, Buzzoni, Roberto, additional, Mazzaferro, Vincenzo, additional, Coppa, Jorgelina Clara, additional, Damato, Angela, additional, Seregni, Ettore, additional, Formisano, Barbara, additional, and Pelosi, Giuseppe, additional

Published
2013
Full Text
View/download PDF

19. Role of FDG-PET as predictive biomarker of pathologic complete response (pCR) in locally advanced rectal cancer (LARC) treated with capecitabine-based neoadjuvant chemoradiation (NACR).

Author

Pietrantonio, Filippo, primary, Di Bartolomeo, Maria, additional, Bampo, Chiara, additional, Valvo, Francesca, additional, Alessi, Alessandra, additional, Crippa, Flavio, additional, Biondani, Pamela, additional, Leo, Ermanno, additional, Milione, Massimo, additional, Dotti, Katia F, additional, Fantini, Simona, additional, Avuzzi, Barbara, additional, Formisano, Barbara, additional, Battaglia, Luigi, additional, Chiruzzi, Chiara, additional, and De Braud, Filippo G., additional

Published
2012
Full Text
View/download PDF

21. Pitfalls in the Diagnosis of Neuroendocrine Tumors: Atypical Clinical and Radiological Findings as Cause of Medical Mistakes

Author

Bajetta, Emilio, primary, Catena, Laura, additional, Ducceschi, Monika, additional, Pusceddu, Sara, additional, Milione, Massimo, additional, Maccauro, Marco, additional, Bajetta, Roberto, additional, Procopio, Giuseppe, additional, Buzzoni, Roberto, additional, Formisano, Barbara, additional, Di Guardo, Lorenza, additional, and Platania, Marco, additional

Published
2009
Full Text
View/download PDF

22. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

Author

Bajetta, Emilio, primary, Catena, Laura, additional, Procopio, Giuseppe, additional, De Dosso, Sara, additional, Bichisao, Ettore, additional, Ferrari, Leonardo, additional, Martinetti, Antonia, additional, Platania, Marco, additional, Verzoni, Elena, additional, Formisano, Barbara, additional, and Bajetta, Roberto, additional

Published
2006
Full Text
View/download PDF

23. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors

Author

Pusceddu, Sara, de Braud, Filippo, Concas, Laura, Bregant, Cristina, Leuzzi, Livia, Formisano, Barbara, and Buzzoni, Roberto

Abstract

Abnormal PI3K-AKT-mTOR pathway signalling and autocrine activation of the mTOR pathway, mediated through insulin-like growth factor-1, have been implicated in the proliferation of pancreatic neuroendocrine tumor (pNET) cells. Everolimus, an mTOR inhibitor, has shown antitumor benefit in pNETs alone and in combination with octreotide LAR in RADIANT-1 and RADIANT-3 studies. Although everolimus-based phase II/III trials have improved progression-free survival for pNET, its use has not impacted on prolonging overall survival. Metformin has recently shown some anti-cancer activity in both in vitro and in vivo studies by its indirect properties to decrease insulin and insulin-like growth factor-1 (IGF-1) levels and by its antitumour effect to promote AMPK activation and consequently inhibition to TSC1–2/mTOR complex. In light of even more retrospective evidence of metformin's anticancer activity, a prospective evaluation is required to either confirm or discard these preliminary findings. With the aim to evaluate the antiproliferative effect of metformin in combination with everolimus and octreotide LAR in pancreatic well-differentiated neuroendocrine tumor patients, a single arm, prospective, single center phase II study was designed (MetNET-1 trial, NCT 02294006). Forty-three patients are expected to be evaluated. The study is ongoing, and recruitment is estimated to be completed in August 2016. The results will be anticipated in 2017.

Published
2014
Full Text
View/download PDF

24. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer

Author

Bidoli, Paolo, Stani, Simonetta C., Mariani, Luigi, Candis, Daniela De, Cortinovis, Diego, Aglione, Stefania, Zilembo, Nicoletta, Toffolatti, Luisa, Formisano, Barbara, and Bajetta, Emilio

Subjects
*PLATINUM, *ANTINEOPLASTIC agents, *SMALL cell lung cancer, *TOXICITY testing
Abstract

Purpose: Oxaliplatin (OHP) is a new platinum antineoplastic, while gemcitabine (GEM) is one of the most active drugs against non-small cell carcinoma (NSCLC). The OHP/GEM combination is interesting because the drugs have different mechanisms of action and toxicity profiles. The primary endpoint of this study was to determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of OHP/GEM combination in non-small cell carcinoma of the lung. Methods: Patients with relapsed NSCLC were treated with fixed dose i.v. GEM (1250 mg/m2) on days 1 and 8; followed on day 1 by i.v. OHP over 3 h, starting from 70 mg/m2 with 20 mg/m2 increments, up to 130 mg/m2. We enrolled 19 patients with eastern cooperative oncology group (ECOG) status 0/1=13/6; male/female=13/6. All had received first-line and four second-line chemotherapy. Results: Four patients dropped out. At dose level 2, one patient died of pulmonary embolism; at level 3, two patients died of disease progression. One patient at level 3, refused to continue treatment after allergic reaction (high fever episode) during infusion of third cycle. Fifteen patients were evaluable for toxicity and response. According to a priori statistical considerations, three patients in each of the first three treatment levels and six in the last level were evaluable. No G3–4 toxicity was observed at levels 1 and 2. G3 neutropenia and anemia occurred in 8% of cycles at level 3. Six patients entered level 4 (OHP 130 mg/m2) with 22 courses delivered: G3–4 neutropenia occurred in 9%, G1–2 thrombocytopenia in 18%; other toxicities were mainly limited to G1–2 flu-like syndrome in about one third of patients and G1–2 nausea and vomiting in 5% of courses. There was no myelo-DLT at the highest dose level. There was no neurotoxicity at any level. Treatment was delayed in 12% and dose reduced in 26% of courses. There were 2/15 PR. Conclusions: MTD was not reached. OHP and GEM can probably be administered safely at 130 and 1250 mg/m2, respectively, as first-line therapy. The schedule is being used in a phase II trial. [Copyright &y& Elsevier]

Published
2004
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results